Ratings by JPMorgan (Tessa Romero)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 10/20/2026 | EyePoint Inc. | EYPT | Downgrade | Underweight (Neutral) |
2.99 (0.40) |
-86.62% | Details | |
| 9/23/2026 | WAVE Life Sciences | WVE | New Coverage | Neutral (N/A) |
4.26 (3.18) |
-25.35% | Details | |
| 9/21/2026 | Scholar Rock | SRRK | Maintain | Overweight (N/A) |
|
Details | ||
| 9/8/2026 | Dyne Therapeutics | DYN | Downgrade | Underweight (Neutral) |
24.28 (15.62) |
-35.67% | Details | |
| 8/20/2026 | Edgewise Therapeutics | EWTX | Maintain | Overweight (Overweight) |
|
Details | ||
| 8/19/2026 | Septerna Inc | SEPN | Maintain | Overweight (Overweight) |
|
Details | ||
| 8/17/2026 | EyePoint Inc. | EYPT | Downgrade | Neutral (Overweight) |
14.75 (2.99) |
-79.73% | Details | |
| 8/14/2026 | Oculis Holding AG | OCS | Maintain | Overweight (Overweight) |
|
Details | ||
| 8/14/2026 | Upstream Bio | UPB | Maintain | Neutral (Neutral) |
|
Details | ||
| 8/13/2026 | Scholar Rock | SRRK | Maintain | Overweight (Overweight) |
|
Details | ||
| 8/13/2026 | Cytokinetics | CYTK | Maintain | Overweight (Overweight) |
|
Details | ||
| 8/7/2026 | Agios Pharma | AGIO | Maintain | Neutral (Neutral) |
|
Details | ||
| 8/5/2026 | Seaport Therapeutics | SPTX | Maintain | Overweight (Overweight) |
|
Details | ||
| 6/25/2026 | Lexeo Therapeutics | LXEO | Maintain | Overweight (N/A) |
|
Details | ||
| 6/12/2026 | Upstream Bio | UPB | Downgrade | Neutral (Overweight) |
6.28 (2.74) |
-56.37% | Details | |
| 6/11/2026 | Agios Pharma | AGIO | Maintain | Neutral (Neutral) |
|
Details | ||
| 6/3/2026 | Oculis Holding AG | OCS | Maintain | Overweight (Overweight) |
|
Details | ||
| 5/27/2026 | Xenon Pharmaceuticals | XENE | Maintain | Overweight (Overweight) |
|
Details | ||
| 5/27/2026 | Larimar Therapeutics | LRMR | New Coverage | Overweight (N/A) |
3.45 (2.35) |
-31.88% | Details | |
| 5/26/2026 | Seaport Therapeutics | SPTX | New Coverage | Overweight (N/A) |
17.19 (20.61) |
19.9% | Details | |
| 5/18/2026 | Oculis Holding AG | OCS | Maintain | Overweight (Overweight) |
|
Details | ||
| 5/12/2026 | Xenon Pharmaceuticals | XENE | Maintain | Overweight (Overweight) |
|
Details | ||
| 5/12/2026 | Cytokinetics | CYTK | Maintain | Overweight (Overweight) |
|
Details | ||
| 5/12/2026 | Cytokinetics | CYTK | Maintain | Overweight (Overweight) |
|
Details | ||
| 4/9/2026 | Nurix | NRIX | Maintain | Overweight (Overweight) |
|
Details | ||
| 4/6/2026 | Agios Pharma | AGIO | Maintain | Neutral (Neutral) |
|
Details | ||
| 3/24/2026 | Septerna Inc | SEPN | Maintain | Overweight (Overweight) |
|
Details | ||
| 3/17/2026 | Edgewise Therapeutics | EWTX | Maintain | Overweight (Overweight) |
|
Details | ||
| 3/17/2026 | Cytokinetics | CYTK | Maintain | Overweight (Overweight) |
|
Details | ||
| 3/16/2026 | Scholar Rock | SRRK | Maintain | Overweight (Overweight) |
|
Details | ||
| 3/4/2026 | Acadia Pharmaceuticals | ACAD | Maintain | Overweight (Overweight) |
|
Details | ||
| 1/20/2026 | Dyne Therapeutics | DYN | Maintain | Neutral (Neutral) |
|
Details | ||
| 1/20/2026 | Cytokinetics | CYTK | Maintain | Overweight (Overweight) |
|
Details | ||
| 1/9/2026 | Xenon Pharmaceuticals | XENE | Maintain | Overweight (Overweight) |
|
Details | ||
| 1/6/2026 | Agios Pharma | AGIO | Maintain | Neutral (Neutral) |
|
Details | ||
| 11/20/2025 | Biohaven Pharmaceutical Holding | BHVN | Maintain | Overweight (Overweight) |
|
Details | ||
| 11/18/2025 | Xenon Pharmaceuticals | XENE | Maintain | Overweight (Overweight) |
|
Details | ||
| 11/17/2025 | Acadia Pharmaceuticals | ACAD | Maintain | Overweight (Overweight) |
|
Details | ||
| 11/14/2025 | Dyne Therapeutics | DYN | Maintain | Neutral (Neutral) |
|
Details | ||
| 11/14/2025 | Edgewise Therapeutics | EWTX | Maintain | Overweight (Overweight) |
|
Details | ||
| 11/5/2025 | Biohaven Pharmaceutical Holding | BHVN | Maintain | Overweight (N/A) |
|
Details | ||
| 9/29/2025 | Acadia Pharmaceuticals | ACAD | Maintain | Overweight (Overweight) |
|
Details | ||
| 9/16/2025 | Neumora Therapeutics | NMRA | Downgrade | Underweight (Neutral) |
1.62 (0.38) |
-76.54% | Details | |
| 8/19/2025 | Edgewise Therapeutics | EWTX | Maintain | Overweight (Overweight) |
|
Details | ||
| 7/28/2025 | Upstream Bio | UPB | Maintain | Overweight (Overweight) |
|
Details | ||
| 7/24/2025 | Acadia Pharmaceuticals | ACAD | Maintain | Overweight (Overweight) |
|
Details | ||
| 7/15/2025 | Dyne Therapeutics | DYN | Maintain | Neutral (Neutral) |
|
Details | ||
| 6/23/2025 | Dyne Therapeutics | DYN | Maintain | Neutral (Neutral) |
|
Details | ||
| 6/18/2025 | Biohaven Pharmaceutical Holding | BHVN | Maintain | Overweight (Overweight) |
|
Details | ||
| 6/9/2025 | Cytokinetics | CYTK | Maintain | Overweight (N/A) |
|
Details | ||
| 6/6/2025 | Acadia Pharmaceuticals | ACAD | Maintain | Overweight (N/A) |
|
Details | ||
| 5/30/2025 | Lexeo Therapeutics | LXEO | Maintain | Overweight (Overweight) |
|
Details | ||
| 5/27/2025 | EyePoint Pharmaceuticals, Inc. | EYPT | Maintain | Overweight (N/A) |
|
Details | ||
| 5/16/2025 | Edgewise Therapeutics | EWTX | Maintain | Overweight (Overweight) |
|
Details | ||
| 5/16/2025 | Acadia Pharmaceuticals | ACAD | Maintain | Overweight (Overweight) |
|
Details | ||
| 5/15/2025 | Xenon Pharmaceuticals | XENE | Maintain | Overweight (Overweight) |
|
Details | ||
| 5/13/2025 | EyePoint Pharmaceuticals, Inc. | EYPT | Maintain | Overweight (Overweight) |
|
Details | ||
| 5/12/2025 | Dyne Therapeutics | DYN | Maintain | Neutral (Neutral) |
|
Details | ||
| 5/8/2025 | Upstream Bio | UPB | Maintain | Overweight (Overweight) |
|
Details | ||
| 3/20/2025 | Dyne Therapeutics | DYN | Maintain | Neutral (N/A) |
|
Details | ||
| 3/5/2025 | Biohaven Pharmaceutical Holding | BHVN | Maintain | Overweight (Overweight) |
|
Details | ||
| 3/3/2025 | Agios Pharma | AGIO | Maintain | Neutral (Neutral) |
|
Details | ||
| 3/3/2025 | Acadia Pharmaceuticals | ACAD | Maintain | Overweight (Overweight) |
|
Details | ||
| 2/14/2025 | Edgewise Therapeutics | EWTX | Maintain | Overweight (Overweight) |
|
Details | ||
| 2/14/2025 | Biohaven Pharmaceutical Holding | BHVN | Maintain | Overweight (N/A) |
|
Details | ||
| 11/5/2024 | Neumora Therapeutics | NMRA | Downgrade | Neutral (Overweight) |
11.17 (1.62) |
-85.5% | Details | |
| 11/5/2024 | Upstream Bio | UPB | New Coverage | Overweight (N/A) |
24.76 (6.28) |
-74.64% | Details | |
| 10/24/2024 | Dyne Therapeutics | DYN | Downgrade | Neutral (Overweight) |
33.39 (24.28) |
-27.28% | Details | |
| 10/24/2024 | Seres Therapeutics | MCRB | Downgrade | Underweight (Neutral) |
0.78 (2.09) |
167.95% | Details | |
| 10/3/2024 | Biohaven Pharmaceutical Holding | BHVN | Maintain | Overweight (N/A) |
|
Details | ||
| 9/4/2024 | Cytokinetics | CYTK | Maintain | Overweight (N/A) |
|
Details | ||
| 8/13/2024 | EyePoint Pharmaceuticals, Inc. | EYPT | Maintain | Overweight (N/A) |
|
Details | ||
| 8/12/2024 | Edgewise Therapeutics | EWTX | Maintain | Overweight (N/A) |
|
Details | ||
| 7/9/2024 | Edgewise Therapeutics | EWTX | Maintain | Overweight (N/A) |
|
Details | ||
| 7/9/2024 | Dyne Therapeutics | DYN | Maintain | Overweight (N/A) |
|
Details | ||
| 6/24/2024 | Cytokinetics | CYTK | Maintain | Overweight (N/A) |
|
Details | ||
| 6/14/2024 | Agios Pharma | AGIO | New Coverage | Neutral (N/A) |
47.97 (37.00) |
-22.87% | Details | |
| 6/4/2024 | EyePoint Pharmaceuticals, Inc. | EYPT | Maintain | Overweight (N/A) |
|
Details | ||
| 5/29/2024 | Biohaven Pharmaceutical Holding | BHVN | Maintain | Overweight (N/A) |
|
Details | ||
| 4/29/2024 | Sana Biotechnology | SANA | Maintain | Neutral (N/A) |
|
Details | ||
| 3/25/2024 | Acadia Pharmaceuticals | ACAD | Maintain | Overweight (N/A) |
|
Details | ||
| 3/18/2024 | Neumora Therapeutics | NMRA | Maintain | Overweight (N/A) |
|
Details | ||
| 3/1/2024 | Acadia Pharmaceuticals | ACAD | Maintain | Overweight (N/A) |
|
Details | ||
| 2/23/2024 | Biohaven Pharmaceutical Holding | BHVN | Maintain | Overweight (N/A) |
|
Details | ||
| 1/22/2024 | EyePoint Pharmaceuticals, Inc. | EYPT | New Coverage | Overweight (N/A) |
22.86 (14.75) |
-35.48% | Details | |
| 1/3/2024 | Dyne Therapeutics | DYN | Maintain | Overweight (N/A) |
|
Details | ||
| 1/2/2024 | Cytokinetics | CYTK | Maintain | Overweight (N/A) |
|
Details | ||
| 11/28/2023 | Lexeo Therapeutics | LXEO | New Coverage | Overweight (N/A) |
11.30 (2.80) |
-75.22% | Details | |
| 11/20/2023 | Biohaven Pharmaceutical Holding | BHVN | Maintain | Overweight (N/A) |
|
Details | ||
| 11/14/2023 | Edgewise Therapeutics | EWTX | Maintain | Overweight (N/A) |
|
Details | ||
| 11/7/2023 | Neumora Therapeutics | NMRA | Maintain | Overweight (N/A) |
|
Details | ||
| 10/30/2023 | Cytokinetics | CYTK | Maintain | Overweight (N/A) |
|
Details | ||
| 10/10/2023 | Acadia Pharmaceuticals | ACAD | Upgrade | Overweight (Neutral) |
21.68 (19.73) |
-8.99% | Details | |
| 10/10/2023 | Neumora Therapeutics | NMRA | New Coverage | Overweight (N/A) |
12.14 (11.17) |
-7.99% | Details | |
| 8/22/2023 | Y-mAbs Therapeutics | YMAB | Maintain | Underweight (N/A) |
|
Details | ||
| 8/16/2023 | Biohaven Pharmaceutical Holding | BHVN | Maintain | Overweight (N/A) |
|
Details | ||
| 8/7/2023 | Acadia Pharmaceuticals | ACAD | Maintain | Neutral (N/A) |
|
Details | ||
| 7/17/2023 | Acadia Pharmaceuticals | ACAD | Maintain | Neutral (N/A) |
|
Details | ||
| 6/30/2023 | Edgewise Therapeutics | EWTX | Maintain | Overweight (N/A) |
|
Details | ||
| 6/22/2023 | Cytokinetics | CYTK | Maintain | Overweight (N/A) |
|
Details | ||
| 6/16/2023 | Biohaven Pharmaceutical Holding | BHVN | Maintain | Overweight (N/A) |
|
Details | ||
| 5/17/2023 | Biohaven Pharmaceutical Holding | BHVN | Maintain | Overweight (N/A) |
|
Details | ||
| 5/16/2023 | Edgewise Therapeutics | EWTX | Maintain | Overweight (N/A) |
|
Details | ||
| 4/25/2023 | Biohaven Pharmaceutical Holding | BHVN | Maintain | Overweight (N/A) |
|
Details | ||
| 4/25/2023 | Xenon Pharmaceuticals | XENE | Maintain | Overweight (N/A) |
|
Details | ||
| 4/21/2023 | Seres Therapeutics | MCRB | New Coverage | Neutral (N/A) |
6.26 (2.09) |
-66.61% | Details | |
| 3/20/2023 | Cytokinetics | CYTK | Maintain | Overweight (N/A) |
|
Details | ||
| 3/20/2023 | Acadia Pharmaceuticals | ACAD | Maintain | Neutral (N/A) |
|
Details | ||
| 3/8/2023 | Acadia Pharmaceuticals | ACAD | Maintain | Neutral (N/A) |
|
Details | ||
| 2/28/2023 | Edgewise Therapeutics | EWTX | Maintain | Overweight (N/A) |
|
Details | ||
| 1/4/2023 | Xenon Pharmaceuticals | XENE | Maintain | Overweight (N/A) |
|
Details | ||
| 1/4/2023 | Biohaven Pharmaceutical Holding | BHVN | New Coverage | Overweight (N/A) |
13.88 (13.88) |
0% | Details | |
| 12/9/2022 | Cytokinetics | CYTK | Maintain | Overweight (N/A) |
|
Details | ||
| 11/14/2022 | Xenon Pharmaceuticals | XENE | Maintain | Overweight (N/A) |
|
Details | ||
| 11/14/2022 | Acadia Pharmaceuticals | ACAD | Maintain | Neutral (N/A) |
|
Details | ||
| 10/31/2022 | Y-mAbs Therapeutics | YMAB | Downgrade | Underweight (Neutral) |
8.85 (8.61) |
-2.71% | Details | |
| 8/2/2022 | Sana Biotechnology | SANA | New Coverage | Neutral (N/A) |
6.68 (2.33) |
-65.12% | Details | |
| 8/2/2022 | Cytokinetics | CYTK | New Coverage | Overweight (N/A) |
42.33 (61.23) |
44.65% | Details | |
| 8/2/2022 | Agios Pharma | AGIO | New Coverage | Neutral (N/A) |
21.57 (47.97) |
122.39% | Details | |
| 8/2/2022 | Acadia Pharmaceuticals | ACAD | New Coverage | Neutral (N/A) |
14.69 (19.73) |
34.31% | Details | |
| 7/21/2022 | Xenon Pharmaceuticals | XENE | New Coverage | Overweight (N/A) |
32.69 (35.34) |
8.11% | Details | |
| 1/6/2022 | Edgewise Therapeutics | EWTX | Maintain | Overweight (N/A) |
|
Details | ||
| 12/31/2021 | Y-mAbs Therapeutics | YMAB | Maintain | Neutral (N/A) |
|
Details | ||
| 11/16/2021 | Y-mAbs Therapeutics | YMAB | Downgrade | Neutral (Overweight) |
22.45 (8.61) |
-61.65% | Details | |
| 11/2/2021 | Edgewise Therapeutics | EWTX | Maintain | Overweight (N/A) |
|
Details | ||
| 6/28/2021 | Global Blood Therapeutics | GBT | Downgrade | Neutral (Overweight) |
36.44 (68.49) |
87.95% | Details | |
| 4/20/2021 | Edgewise Therapeutics | EWTX | New Coverage | Overweight (N/A) |
27.08 (39.31) |
45.16% | Details | |
| 3/22/2021 | Y-mAbs Therapeutics | YMAB | New Coverage | Overweight (N/A) |
35.00 (8.61) |
-75.4% | Details | |
| 11/9/2020 | Rigel Pharmaceuticals | RIGL | Downgrade | Neutral (Overweight) |
2.74 (48.13) |
1656.57% | Details | |
| 9/26/2019 | Rigel Pharmaceuticals | RIGL | New Coverage | Overweight (N/A) |
1.71 (48.13) |
2714.62% | Details |
